Mitochondrial Dysfunction in Systemic Lupus Erythematosus with a Focus on Lupus Nephritis

Area of Science:

• Immunology
• Pathophysiology
• Mitochondrial Biology

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease primarily affecting women of child-bearing age.
• Immune dysfunction in SLE involves disrupted apoptosis, leading to interferon (IFN) stimulation, autoantibodies, and organ damage.
• Lupus nephritis (LN), a severe SLE complication, affects 30-40% of patients and involves renal cell mitochondrial abnormalities.

Purpose of the Study:

• To detail the physiopathological link between mitochondrial dysfunction and SLE disease activity.
• To explore mitochondria as potential biomarkers and therapeutic targets in SLE, particularly in LN.
• To review the role of defective mitophagy in exacerbating SLE-related immune dysregulation.

Main Methods:

• Review of recent studies on mitochondrial homeostasis in SLE and LN.
• Analysis of pathways linking mitochondrial dysfunction to type 1 IFN production.
• Exploration of cell-free mitochondrial DNA as a potential biomarker.

Main Results:

• Mitochondrial dysfunction significantly contributes to SLE pathogenesis by enhancing type 1 IFN production.
• Defective mitophagy exacerbates immune dysregulation in SLE.
• Mitochondrial abnormalities in renal cells correlate with disease progression and fibrosis in LN.

Conclusions:

• Mitochondrial dysfunction is a key factor in SLE and LN pathogenesis.
• Mitochondria represent promising targets for novel biomarkers and therapeutics in SLE and LN.
• Targeting mitochondrial dysfunction, potentially with drugs like metformin, may improve immune responses and clinical outcomes.